At A Glance
- Semaglutide is a GLP-1 receptor agonist.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist.
- Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist under clinical investigation.
- Results from different trials cannot be treated as a direct ranking unless populations, designs, durations, and comparators are comparable.
What Is The Simplest Way To Tell Them Apart?
The clearest first difference is receptor pharmacology. Semaglutide activates GLP-1 receptors. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide was designed to activate GIP, GLP-1, and glucagon receptors.
More receptor targets do not automatically mean better for every outcome or person. Dose, balance of activity, study population, side effects, treatment duration, and clinical indication all affect what a trial result means.
Are All Three Approved Medicines?
No. Health Canada's database lists authorized drug products containing semaglutide and tirzepatide for specific indications and presentations. Retatrutide remains an investigational compound in registered clinical trials and should not be represented as an approved medicine.
A vial sold online under a familiar active ingredient name is not automatically equivalent to an authorized finished drug. Authorization belongs to the exact product, manufacturer, formulation, presentation, and labelled use.
The Differences At A Glance
This comparison separates mechanism, regulatory status, and evidence stage rather than declaring a winner.
| Study or context | What was explored | What it tells us | Useful context |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist studied and authorized in specific finished drug products | One incretin receptor target with large clinical development programs | Approval and storage instructions apply to exact authorized products, not any material using the name |
| Tirzepatide | Dual GIP and GLP-1 receptor agonist studied and authorized in specific products | Two receptor targets and its own clinical evidence base | Cannot be treated as semaglutide with an extra ingredient |
| Retatrutide | Triple GIP, GLP-1, and glucagon receptor agonist in clinical trials | Phase 2 results and ongoing or completed phase 3 programs inform development | Investigational status means it is not interchangeable with an authorized drug |
Can I Compare The Headline Weight Loss Numbers?
Only cautiously. Separate trials can differ in eligibility, baseline characteristics, dose escalation, adherence, duration, statistical estimand, lifestyle program, missing data, and adverse event handling. A larger number in one study is not a controlled head to head result.
For a fair comparison, look for randomized head to head trials or systematic analyses that account for design differences. Also separate an approved indication from an experimental outcome reported during development.
Common Questions About Semaglutide Tirzepatide Retatrutide Comparison
Is tirzepatide the same as semaglutide?+
No. They are different molecules. Semaglutide targets GLP-1 receptors, while tirzepatide targets GIP and GLP-1 receptors.
Is retatrutide approved in Canada?+
No authorized retatrutide drug appears in Health Canada's Drug Product Database. It remains an investigational compound in clinical development.
Does three receptor targets mean retatrutide is automatically better?+
No. Receptor count alone cannot determine overall benefit, risk, tolerability, or suitability. Those questions require comparative clinical evidence and regulatory review.
Can online research material be considered equivalent to an approved drug?+
No. Authorization and supporting evidence apply to an exact manufacturer, formulation, presentation, and labelled use.
Sources
Want to go a little deeper? These links take you to the studies and official records behind the guide. Study registries describe the plan; published papers report the findings.
- Drug Product Database: Access the DatabaseHealth Canada · 2026
Provides a searchable record of drugs authorized for sale in Canada, including product status and Drug Identification Numbers.
- FDA Approves New Medication for Chronic Weight ManagementU.S. Food and Drug Administration · 2023
Describes tirzepatide as activating GIP and GLP-1 receptors and summarizes the evidence supporting the Zepbound authorization.
- Triple Hormone Receptor Agonist Retatrutide for Obesity: A Phase 2 TrialNew England Journal of Medicine · 2023
Reports the phase 2 randomized trial and identifies retatrutide as a GIP, GLP-1, and glucagon receptor agonist.
- TRIUMPH 3: Retatrutide in Participants With Obesity and Cardiovascular DiseaseClinicalTrials.gov · 2026
Current phase 3 trial registry record showing retatrutide's investigational clinical development status.